Mya Tran

50 years.. and countless lives saved! Dr. Einhorn - we’re so grateful for you ♥️ #TesticularCancerCure #ResearchCureCancer @IUCancerCenter

MTAP loss is frequent in oncogene-driven #NSCLC, with highest rates in ALK+ (up to 45%), followed by RET+ (up to 36%) and EGFR+ (up to 24%). IHC and NGS may be complementary for detection. #PRMT5i shows activity regardless of prior TKI exposure. PRMT5i + targeted therapy may outperform monotherapy in models with at least partial TKI sensitivity. @RETpositive @AlkPositive @EGFRResisters @DanaFarber @GustaveRoussy @Annals_Oncology

Never underestimate the power of one. One patient can change everything. Discovery lies in the outliers. Ask why. Follow the science. 🧪🧬🔬 #research #medtwitter #sclc #lcsm #biomarkers #precisionmedicine @SclcSMASHERS @TheShieldsLab @IUCancerCenter @IUMedSchool @MoffittNews @ktgminton @hilalozakinci @OTtheScientist @PareshKumaaar @MyaPrecisionG @MCT_AACR @AACR aacrjournals.org/mct/article-ab…

Is there a role for stigma in lung cancer? What about in small cell lung cancer? No!🚫👎🙅‍♀️ 1) no one deserves lung cancer. 2) lung cancer can impact anyone with lungs, that’s everyone! 3) stigma hurts others with tangible negative impacts - delays in screening, follow ups, treatments and impacts how patients feel. Stigma, out the door. 🚪 You’re not welcome here. ✌️ @lungoncdoc @LUNGevity @SclcSMASHERS @IUCancerCenter @ASCO @TheShieldsLab

This Tue, you're in for a treat on #HealthcareUnfiltered as @drshieldsmd of @IUCancerCenter joins me to share her inspiring career journey & why she focuses on small cell lung cancer. As a physician scientist, she will share how rapid advances in lung cancer shape her lab work.

What’s the key 🔑 ingredient to being a translational cancer researcher 🧬🔬? Both a physician and a scientist 👩🏼‍🔬? 1) It takes a team. Science and medicine is a team effort, and we cannot do it alone. “Rising tides floats all boats.” 🛥️ Lift up your team, be kind, work hard, have joy, and show appreciation. Often. 2) Be present. Balance is about being where you are - when you are there. Hack back at distractions - emails 📧 , alerts 🚨, and stay present. 💝 #lcsm #sclc @TheShieldsLab @lungevity @IUCancerCenter @nireyal

cell.com/cancer-cell/fu… ARTMIS-001, phase 1a/b study of HS-20093 (GSK5764227), a B7H3 TOPO1i ADC, in lung cancer published on @Cancer_Cell 52.3% ORR in ES-SCLC (N=65) 22.4% ORR in NSCLC (N=152) B7-H3 expression levels did not significantly correlate with clinical efficacy

Data on izalontamab brengitecan (iza-bren, EGFR-HER3 bispecific ADC) in AGA+ NSCLC (excluding common EGFR, reported separately) after standard treatment @JCO_ASCO. In EGFRex20 RR 69.2%, PFS 10.5m. HER2 RR 52.9%, PFS 7.5m. Only 1 case of ILD (G2). ascopubs.org/doi/10.1200/JC…

Opening the door wide with phenomenal clean tolerability evolution, this is the new generation of KRAS G12D inhibitors. 🎯 Both RVMD agents are excellent and advancing fast (daraxonrasib in multiple Ph3s, zoldonrasib with BTD), but the January US safety read for VS-7375 raises the bar on “clean” for next-gen KRAS inhibitors. VS-7375 (GFH375) US Ph1/2a (VS-7375-101, Jan 30 2026 cutoff, N=23 mono escalation): • no >G1 nausea/diarrhea/vomiting (standard prophylaxis), • no >G2 neutropenia, zero drug-related LFT abnormalities. • Any initial G1 events resolved quickly (often within 1–2 weeks) with supportive care. • 900 mg QD cleared with no DLTs; now escalating to 1200 mg QD for optimal exposure in mono & combos. Unlike the early-generation KRAS G12D agents (e.g. MRTX1133, discontinued due to tolerability issues), this next wave delivers clean profiles from day one, enabling smooth dose escalation and combo potential. Builds on: • WCLC 2025 NSCLC (96% prior ICI): 🔸️68.8% ORR (11/16) + 93.8% DCR at 600 mg QD RP2D • ESMO 2025 2L+ PDAC: 🔸️58.3% ORR in true 2L (n=12 at 600 mg), overall ~41% (n=59), DCR 96.7%, mPFS 5.52 mo In a field where 43–57% of stage IV PDAC patients never even see 1L chemo and <30% reach 3L, this tolerability edge isn’t just exciting, it’s potentially practice-changing. @FDAOncology momentum accelerating, Fast Track (PDAC all lines), China Breakthrough + Ph3 2L PDAC, US cetuximab combo advancing, H1 2026 interim. Early conditional approval pathways now realistic? Patients with KRAS G12D PDAC, NSCLC & CRC are yearning for this cleaner safety, both monotherapy and combinations. Real hope on the horizon for thousands. Inclusive, equitable access can’t come soon enough. (Real-world attrition & subtreatment realities in PDAC/NSCLC in follow-up thread, why this changes everything.) @Aiims1742 @DrMakaryFDA @Timothee_MD @BenjaminBesseMD @Tony_Calles

No real progress was made in small cell lung cancer for almost four decades. Recent studies with new agents brought hope. Deciding what therapy for which patients still remains a challenge. Treatment options for #SCLC after progression are limited. In @TheShieldsLab at @IUCancerCenter, we exclusively focus on identifying novel biomarkers, targets, and combinations for #SCLC. Give us a follow if you want to hear more about SCLC research and updates! @LUNGevity @SclcSMASHERS @OTtheScientist @PareshKumaaar

The waterfall plot of DV in #HER2low urothelial cancer is extremely similar to the first ever data we saw with T-DXd in HER2-low breast cancer in 2018. Bodes well for the future of HER2 targeting in urothelial cancer.

Thank you to the organizers @LuisRaezMD @EddieSantosMD, Dr. Miguel Colon-Donate @noridza @mecmededucation for the opportunity to speak on the exciting #SCLC advances, potential barriers, & opportunities for future trials at #WCS26 @SclcSMASHERS

Progress!

So proud of the novel research on small cell lung cancer that has been peer reviewed, accepted, & presented at poster sessions by @TheShieldsLab (PI @drshieldsmd) at @IUCancerCenter, since the lab was formed in 2023! #researchcurescancer #smallbutmighty #thisishowwedoit #SCLC

New research insights were published in JCO Precision Oncology by the cancer center’s Bryan P. Schneider, MD, and colleagues. Learn more: ow.ly/U8J350XFLCp. #ResearchCuresCancer #NCIcomprehensive @JCOPO_ASCO

Case report @JTOonline shows acquired ERBB2 amplification as a mechanism of resistance to the HER2 TKI zongertinib. This patient then responded to the HER2 antibody drug conjugate, trastuzumab-deruxtecan. Will combination strategies be the future here? jtocrr.org/article/S2666-…

So interesting! @lcsmchat #lungcancer @IASLC @StephenVLiu @lungoncdoc @DrJNaidoo @ThoracicStudent

Wonderful study. Large part of the resistance to T-DXd derives from PAYLOAD resistance, via SLFN11 loss or efflux pump amplification. Thus, sequencing 2 ADCs with similar payload can lead to cross resistance, while switching payload is more likely to work. jto.org/article/S1556-…

couldn’t agree more 👏🏻🧬

Another incredible genomics paper from Po-Ru Loh’s team just dropped in Nature. The team analyzed whole genome sequence (WGS) data of 900,000 individuals from the UK Biobank and All of Us and report fascinating insights on short tandem repeat (STR) mutations in the human genome. At the core of the paper is the authors’ creative methodologies to overcome the challenges involved in using short read WGS data of unrelated individuals to study germline and somatic repeat expansions. Must read for anyone interested in repeat mutations and genetics of repeat expansion disorders. Hujoel et al. Nature 2026 nature.com/articles/s4158…

1/ Excited to share the latest paper from our group on lung carcinoids. onlinelibrary.wiley.com/doi/10.1111/hi… pubmed.ncbi.nlm.nih.gov/41489019/ A few comments below: